210 related articles for article (PubMed ID: 19660550)
1. Identification and functional dissection of localization signals within ataxin-3.
Antony PM; Mäntele S; Mollenkopf P; Boy J; Kehlenbach RH; Riess O; Schmidt T
Neurobiol Dis; 2009 Nov; 36(2):280-92. PubMed ID: 19660550
[TBL] [Abstract][Full Text] [Related]
2. A mutant ataxin-3 fragment results from processing at a site N-terminal to amino acid 190 in brain of Machado-Joseph disease-like transgenic mice.
Colomer Gould VF; Goti D; Pearce D; Gonzalez GA; Gao H; Bermudez de Leon M; Jenkins NA; Copeland NG; Ross CA; Brown DR
Neurobiol Dis; 2007 Sep; 27(3):362-9. PubMed ID: 17632007
[TBL] [Abstract][Full Text] [Related]
3. Ataxin-3 protein modification as a treatment strategy for spinocerebellar ataxia type 3: removal of the CAG containing exon.
Evers MM; Tran HD; Zalachoras I; Pepers BA; Meijer OC; den Dunnen JT; van Ommen GJ; Aartsma-Rus A; van Roon-Mom WM
Neurobiol Dis; 2013 Oct; 58():49-56. PubMed ID: 23659897
[TBL] [Abstract][Full Text] [Related]
4. Polyglutamine-induced neurodegeneration in SCA3 is not mitigated by non-expanded ataxin-3: conclusions from double-transgenic mouse models.
Hübener J; Riess O
Neurobiol Dis; 2010 Apr; 38(1):116-24. PubMed ID: 20079840
[TBL] [Abstract][Full Text] [Related]
5. Heterogeneous intracellular localization and expression of ataxin-3.
Trottier Y; Cancel G; An-Gourfinkel I; Lutz Y; Weber C; Brice A; Hirsch E; Mandel JL
Neurobiol Dis; 1998 Nov; 5(5):335-47. PubMed ID: 10069576
[TBL] [Abstract][Full Text] [Related]
6. [Polyglutamine-expanded ataxin-3 is degraded by autophagy].
Xiao H; Tang J; Hu Z; Tan J; Tang B; Jiang Z
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2010 Feb; 27(1):23-8. PubMed ID: 20140862
[TBL] [Abstract][Full Text] [Related]
7. Evidence for proteasome involvement in polyglutamine disease: localization to nuclear inclusions in SCA3/MJD and suppression of polyglutamine aggregation in vitro.
Chai Y; Koppenhafer SL; Shoesmith SJ; Perez MK; Paulson HL
Hum Mol Genet; 1999 Apr; 8(4):673-82. PubMed ID: 10072437
[TBL] [Abstract][Full Text] [Related]
8. Silencing ataxin-3 mitigates degeneration in a rat model of Machado-Joseph disease: no role for wild-type ataxin-3?
Alves S; Nascimento-Ferreira I; Dufour N; Hassig R; Auregan G; Nóbrega C; Brouillet E; Hantraye P; Pedroso de Lima MC; Déglon N; de Almeida LP
Hum Mol Genet; 2010 Jun; 19(12):2380-94. PubMed ID: 20308049
[TBL] [Abstract][Full Text] [Related]
9. Decreased antioxidant enzyme activity and increased mitochondrial DNA damage in cellular models of Machado-Joseph disease.
Yu YC; Kuo CL; Cheng WL; Liu CS; Hsieh M
J Neurosci Res; 2009 Jun; 87(8):1884-91. PubMed ID: 19185026
[TBL] [Abstract][Full Text] [Related]
10. Caspase-mediated proteolysis of the polyglutamine disease protein ataxin-3.
Berke SJ; Schmied FA; Brunt ER; Ellerby LM; Paulson HL
J Neurochem; 2004 May; 89(4):908-18. PubMed ID: 15140190
[TBL] [Abstract][Full Text] [Related]
11. Calpain-mediated ataxin-3 cleavage in the molecular pathogenesis of spinocerebellar ataxia type 3 (SCA3).
Hübener J; Weber JJ; Richter C; Honold L; Weiss A; Murad F; Breuer P; Wüllner U; Bellstedt P; Paquet-Durand F; Takano J; Saido TC; Riess O; Nguyen HP
Hum Mol Genet; 2013 Feb; 22(3):508-18. PubMed ID: 23100324
[TBL] [Abstract][Full Text] [Related]
12. Machado-Joseph disease/spinocerebellar ataxia type 3.
Paulson H
Handb Clin Neurol; 2012; 103():437-49. PubMed ID: 21827905
[TBL] [Abstract][Full Text] [Related]
13. Ataxin-3 protein and RNA toxicity in spinocerebellar ataxia type 3: current insights and emerging therapeutic strategies.
Evers MM; Toonen LJ; van Roon-Mom WM
Mol Neurobiol; 2014 Jun; 49(3):1513-31. PubMed ID: 24293103
[TBL] [Abstract][Full Text] [Related]
14. Recruitment and the role of nuclear localization in polyglutamine-mediated aggregation.
Perez MK; Paulson HL; Pendse SJ; Saionz SJ; Bonini NM; Pittman RN
J Cell Biol; 1998 Dec; 143(6):1457-70. PubMed ID: 9852144
[TBL] [Abstract][Full Text] [Related]
15. [Recent advances in molecular genetics of spinocerebellar ataxia type 3/Machado-Joseph disease].
Jia D; Jiang H; Tang B
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2008 Dec; 25(6):660-2. PubMed ID: 19065526
[TBL] [Abstract][Full Text] [Related]
16. Nuclear localization of ataxin-3 is required for the manifestation of symptoms in SCA3: in vivo evidence.
Bichelmeier U; Schmidt T; Hübener J; Boy J; Rüttiger L; Häbig K; Poths S; Bonin M; Knipper M; Schmidt WJ; Wilbertz J; Wolburg H; Laccone F; Riess O
J Neurosci; 2007 Jul; 27(28):7418-28. PubMed ID: 17626202
[TBL] [Abstract][Full Text] [Related]
17. Proteotoxic stress increases nuclear localization of ataxin-3.
Reina CP; Zhong X; Pittman RN
Hum Mol Genet; 2010 Jan; 19(2):235-49. PubMed ID: 19843543
[TBL] [Abstract][Full Text] [Related]
18. Full-length expanded ataxin-3 enhances mitochondrial-mediated cell death and decreases Bcl-2 expression in human neuroblastoma cells.
Tsai HF; Tsai HJ; Hsieh M
Biochem Biophys Res Commun; 2004 Nov; 324(4):1274-82. PubMed ID: 15504352
[TBL] [Abstract][Full Text] [Related]
19. CK2-dependent phosphorylation determines cellular localization and stability of ataxin-3.
Mueller T; Breuer P; Schmitt I; Walter J; Evert BO; Wüllner U
Hum Mol Genet; 2009 Sep; 18(17):3334-43. PubMed ID: 19542537
[TBL] [Abstract][Full Text] [Related]
20. Ataxin-3 is translocated into the nucleus for the formation of intranuclear inclusions in normal and Machado-Joseph disease brains.
Fujigasaki H; Uchihara T; Koyano S; Iwabuchi K; Yagishita S; Makifuchi T; Nakamura A; Ishida K; Toru S; Hirai S; Ishikawa K; Tanabe T; Mizusawa H
Exp Neurol; 2000 Oct; 165(2):248-56. PubMed ID: 10993685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]